Usefullness of non-invasive biomarkers in the treatment wiht bronchial asthma

Usefullness of non-invasive biomarkers in the treatment wiht bronchial asthma - Non-invasive biomarkers in asthma treatment

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001768

Enrollment

Registered

2009-03-12

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Inhaled bronchodilator

salbutamol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult mild and moderate persistent asthma treating with inhaled corticosteroids according to GINA2006 guideline

Exclusion criteria

Exclusion criteria: 1. Obstructive pulmonary disease; COPD, bronchiectasis, choronic bbronchitis 2. Tuberculosis, other respiratory infection 3. Allergy for salbutamol 4. Pregnancy and lactation 5. Moderate and severe asthma exacerbation 6. inappropriate patients from the doctor's viewpoint

Design outcomes

Primary

Measure	Time frame
1.Routine respiratory function tests: spirometry,body plethysmography and closing volume at atable period, before and 15min after inhaled bronchodilator during mild exacerbation. 2.Non-invasive biomarker; impulse oscillometry: R5,R20,R5-R20,X5,AX, and exhaled nitric oxide at stable period, before and 15min after inhaled bronchodilator during mild exacerbation.	—

Secondary

Measure	Time frame
Scores of questionnaires for QOL	—

Countries

Japan

Contacts

Public ContactHiroshi Tanaka

Sapporo Medical University School of Medicne Third Department of Internal Medicine

011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026